A Biotech ETF Broke Through Some Key Resistance
Insights - A key biotech ETF broke through some key resistance levels on Thursday, which is good for the sector. Can it overcome broader market concerns?
Read nowAuthor Archives: Editorial Staff
The Market Makes All-Time Highs While Biotech Continues the Malaise
Insights - Before we get into the event of the week – the ASCO abstract drop on Wednesday evening – lets take a look at what’s been … Continue Reading
Read now
Sarepta: Big Plans for the Second Half
Research - Sarepta (SRPT) will file a NDA and get 5 new trials off the ground in the next 7 months.
Read nowA Roundup our Top Stories from the Week
Insights - PropThink published an ASCO 2014 preview early this week, highlighting events that will capture Wall Street’s interest as abstracts are published online and presentations kick off at … Continue Reading
Read nowA Good Reminder: Most Drugs Won’t Make the Cut
Recap - We count at least nine failures of one sort or another (Complete Response Letters, failed trials) in the last five days from companies such as Pozen (POZN), … Continue Reading
Read nowRecap: A Mixed Bag in Biopharma Earnings
Recap - An update from Sarepta Therapeutics (SRPT) first thing on Monday morning caught the attention of the biotech world – and sent one of our 2014 recommendations to PropThink Premium … Continue Reading
Read now
On Sourcing Investment Ideas and A Few Simple Growth Criteria
Insights - Determining the attractiveness of a revenue-generating company vs. a development-stage opportunity varies tremendously in healthcare, but there are a few quantitative metrics that can be used … Continue Reading
Read now